Neuromuscular Disorders
Viral and retroviral myositis
Jun. 16, 2026
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
CLIPPERS …
- Updated 01.14.2026
- Released 09.12.2012
- Expires For CME 01.14.2029
CLIPPERS
Introduction
Overview
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is an inflammatory condition of the central nervous system of unknown etiology, primarily involving the brainstem and cerebellum. Symptoms of CLIPPERS include subacute onset of brainstem symptoms--most prominently, ataxia, diplopia, dysarthria, and altered facial sensation. The core radiological features are punctate or curvilinear perivascular gadolinium enhancement, typically centered in the pons and adjacent cerebellum. Neuropathological examination of affected areas reveals a perivascular lymphocytic inflammation with predominant CD4+ T cells. Clinical and radiological features respond to high-dose corticosteroid treatment, but continuous oral corticosteroid treatment and steroid-sparing agents are needed to prevent relapses and reduce the risk for subsequent parenchymal atrophy and chronic ataxia. The differential diagnosis for CLIPPERS is broad, and a careful workup is needed to ensure appropriate treatment is offered.
Key points
• CLIPPERS is a relapsing subacute brainstem syndrome presenting with symptoms such as ataxia, diplopia, dysarthria, and altered facial sensation. | |
• MRI shows punctate or curvilinear gadolinium enhancement in the pons and adjacent cerebellum. Lesions may extend cranially into the basal ganglia or caudally towards the cervico-thoracal medulla. | |
• Neuropathological examination of affected regions shows a perivascular lymphocytic inflammation that may involve both white and grey matter, with a CD4+ T cell predominance. | |
• No diagnostic biomarker is available for CLIPPERS, and the differential diagnoses is broad, requiring a careful workup of alternative causes. Proposed diagnostic criteria help differentiate CLIPPERS from CLIPPERS mimics and, in typical cases, allow for diagnosis without brain biopsy. | |
• Both clinical symptoms and MRI abnormalities respond well to high-dose intravenous methylprednisolone, but continuous oral corticosteroid treatment and steroid-sparing agents are often needed to prevent relapses. |
Historical note and terminology
CLIPPERS was initially described by Dr. Pittock and colleagues in 2010, based on a case series of eight patients with similar clinical, radiological, and pathological features and a robust response to corticosteroid treatment (40). Following the original description, a number of smaller and larger case series and case reports described similar patients, expanding the clinical and pathological features (06; 16; 21; 23; 45; 49; 56; 43; 24). Patients with alternative diagnoses initially suspected to have CLIPPERS have also been reported. These include CNS lymphoma (11; 31), systemic T cell lymphoma (36), Hodgkins lymphoma (34), primary cerebral angiitis (09), anti-MOG-associated disease (46), multiple sclerosis (38), and chronic hepatitis B infection (57). Such cases have led to discussion of whether CLIPPERS represents a unique condition or merely a group of disorders that share the early features of ataxia, brainstem symptoms, and pontine perivascular contrast-enhancement on MRI. A large case series of 35 patients with a presumed diagnosis of CLIPPERS (of whom 23 were ultimately diagnosed with this disorder) has led to proposed diagnostic criteria for differentiating CLIPPERS from its mimics (55).
The term SLIPPERS (supratentorial lymphocytic inflammation with parenchymal perivascular enhancement responsive to steroids) was coined in 2015 to describe a variant of CLIPPERS that was isolated to the supratentorial component (04). To date, few cases of SLIPPERS have been documented in the literature. Whether SLIPPERS should be called “CLIPPERS with hemispheric involvement” or is its own separate disease entity remains to be elucidated (01), and questions remain whether CLIPPERS is a disease or a syndrome. Another group suggested the name “CNS-CLIPERS” for CNS-chronic lymphocytic inflammation with perivascular enhancement responsive to steroids to cover more phenotypes (28).
Clinical manifestations
Presentation and course
Patients with CLIPPERS present with subacute brainstem symptoms--most often ataxia, diplopia, dysarthria, and altered facial sensation (40; 49; 61). Less common brainstem features include pseudobulbar affect, tinnitus, nystagmus, facial palsy, dizziness, nausea, hiccups, and palatal myoclonus (40; 45; 49). Other features may include long-tract signs, including paraparesis, sphincter dysfunction, and cognitive dysexecutive symptoms (40; 45; 49; 08). The latter correspond to the presence of gadolinium enhancement in regions adjacent to the primarily affected brainstem.
Without treatment, symptoms progress, and relapses are common. In a study of 12 patients with CLIPPERS, the annualized relapse rate was 0.5 (0.25 to 2.8), with a mean residual EDSS score of 1.9 (range 0 to 7). Relapses seemed to occur when oral prednisone dosage was titrated below 20 mg per day, but patients responded well to an increase of corticosteroids (49).
Diagnostic criteria are proposed based on an assessment of 35 patients with a presumed diagnosis of CLIPPERS, of whom 23 were ultimately diagnosed with this disorder (Table 1).
Table 1. Proposed Diagnostic Criteria for CLIPPERS
|
I. Clinical | ||
|
A. Subacute pontocerebellar dysfunction, with or without other CNS symptoms such as cognitive dysfunction and myelopathy. | ||
|
B. CNS symptoms responsive to corticosteroid therapy. | ||
|
C. Absence of peripheral nervous system disease. | ||
|
D. Lack of an alternative better explanation for clinical presentation. | ||
|
II. MRI | ||
|
A. Homogenous gadolinium-enhancing nodules without ring enhancement or mass effect predominating in the pons and cerebellum and measuring less than 3 mm in diameter. | ||
|
B. Marked improvement in abnormal gadolinium enhancement with corticosteroid treatment. | ||
|
C. Homogenous T2 signal abnormality where the degree of T2 does not significantly exceed the size of the area of post-gadolinium enhancement. | ||
|
D. Spinal cord lesion with similar T2 and gadolinium-enhancing lesion as above. | ||
|
III. Neuropathology | ||
|
A. Dense lymphocytic inflammation with perivascular predominance and parenchymal diffuse infiltration; both white and grey matter could be involved. | ||
|
B. T cell predominating infiltrates (CD4 > CD8) with variable macrophage components. | ||
|
C. Absence of myelin loss or focal secondary myelin loss. | ||
|
D. Lack of an alternative better explanation for the pathological presentation. | ||
|
| ||
The accuracy of the proposed diagnostic criteria was later evaluated (51). Forty-two patients were followed for a median of 50 months. The sensitivity of the CLIPPERS criteria was 93%, and the specificity was 69%. There were 13 mimics in 42 patients (later confirmed to have systemic and central nervous system lymphomas, primary central nervous system angiitis, and autoimmune gliopathies).
Prognosis and complications
Knowledge about the complications associated with CLIPPERS is limited. Complications may include weight loss, aspiration pneumonia, dysarthria, spasticity, urological complications (urinary retention, incontinence, infection), and decubitus ulcers. Complications often require a multidisciplinary approach involving dietitians, speech therapists, physiotherapists, and psychologists. The degree of neurologic symptoms that persist after stabilization of the inflammation with steroids and/or steroid sparing agents is variable; some patients have minimal residual deficits, whereas others have permanent neurologic disability.
Clinical vignette
A 58-year-old woman had a 4-week history of subacute gait ataxia, dysarthria, and paresthesia of the face, hands, and feet. She had four relapses during the follow-up period from 2007 to 2013. Serial MRI revealed multiple small contrast-enhancing lesions progressively involving the brainstem, the mesencephalon, and, to a lesser degree, the subcortical white matter.
CLIPPERS before and after high-dose intravenous methylprednisolone (MRI) (1)
T1-weighted MRI images after gadolinium in a patient with CLIPPERS demonstrates punctate and curvilinear gadolinium enhancement in the pons and cerebellum on axial (A1) and sagittal (A2) sections. (Contributed by Dr. Daniel Kondzi...
She was treated with steroids and steroid-sparing agents (eg, azathioprine) and responded clinically and radiologically but relapsed each time these treatments were tapered.
When she was diagnosed with CLIPPERS in 2012 (ie, 2 years after the first description of this disorder), she was put on maintenance immunomodulatory treatment, which was subsequently tapered to 5 mg prednisolone once daily together with azathioprine (2.5 mg/kg bodyweight). She did not experience further relapses but remained severely dysarthric and ataxic. Neuroimaging no longer showed any contrast-enhancing lesions, but there was remarkable cortical cerebral and cerebellar atrophy.
Biopsy revealed parenchymal and perivascular inflammatory infiltrates predominantly composed of CD3 + T cells and CD68 + microglia/macrophages. Repeated CSF analysis showed mild lymphocytosis but no oligoclonal bands. Ten years after presentation, the patient was severely dysarthric, moderately cognitively impaired, and wheelchair-bound and had mild involuntary choreiform movements of tongue and hands (modified Ranking scale 4).
Biological basis
Etiology and pathogenesis
The etiology of CLIPPERS is not known.
Based on MRI findings, neuropathology, and response to steroids, CLIPPERS is believed to be inflammatory. Biopsies from affected areas show a predominant perivascular infiltration of CD3+ T cells (40). Most of these are CD4+ T cells, whereas CD8+ T cells, B-cells, and plasma cells are seen in a smaller number (40; 55). A few cases with more predominant perivascular B cell infiltration were described (59). CD68+ histiocytes can be present in moderate numbers, as well as infiltrating macrophages (45; 55). A small number of neutrophils and eosinophils was found in some cases (49; 55). There is also a suggestion that CLIPPERS is mediated by Th17 cells (35). Reactive gliosis and signs of neurodegeneration with variable axonal injury (axonal spheroids and torpedoes) are seen in some specimens (45; 08; 55). This neurodegeneration can be associated with diffuse demyelination, but focal demyelinating lesions, as seen in multiple sclerosis, are not found (55). Demyelination may be secondary to massive inflammation and neurodegeneration. The neuropathological findings in CLIPPERS are generally correlated to the inflammatory pattern seen on MRI but are also found to a lesser extent in regions with normal MRI appearance (08).
A few cases in the literature have suggested autoimmunity secondary to viral infections, such as hepatitis B (57), Epstein-Barr virus (33), or HSV3 (58) or even following Influenza vaccination (20; 58; 42).
Pathological examination is especially important to rule out CLIPPERS mimics in cases with atypical clinical or radiographic features. There are no signs of vessel wall destruction with fibroid necrosis, as seen in vasculitis. Aggregates of histiocytes may resemble loose granulomas but without peripheral lymphocytic cuffing or necrosis, and granulomas generally do not occur (45; 55). Moreover, no light chain restriction or other features of lymphoma are present (08).
The suspected inflammatory nature of CLIPPERS is further substantiated by a number of cases with often transient CSF-specific oligoclonal bands. A target antigen in microstructures within the perivascular space has been proposed (40). Others argue for the role of T cell-mediated cell death (49). Activation and deposition of complement and IgG were observed in a few biopsy-confirmed cases (07).
A possible allergic mediator was proposed due to the elevated serum IgE level in some patients (23). None of these potential mechanisms have been confirmed.
Because some symptoms and signs of CLIPPERS are common features of a variety of diseases, it is not uncommon for patients initially diagnosed with CLIPPERS to be subsequently diagnosed with other disorders. Lymphoma cases are the most commonly described (11; 31; 52; 32; 17; 26). Interestingly, a case of lymphoma in a patient also diagnosed with CLIPPERS was seen in the latest and largest case series (55). CLIPPERS is, thus, a potential premalignant state in some cases. Although most cases do not develop malignancy even after a prolonged follow-up (08; 55), hyperreflexia, elevated protein in CSF, and recurrences less than 1 year after treatment or while on high-dose maintenance steroids are risk factors suggesting an underlying lymphoma (62). Patients with lymphoma tend to have a worse prognosis than those without lymphoma.
The genetics of CLIPPERS are as yet unknown, and no familial clustering has been described thus far. However, in a small study conducted in 12 patients with probable or definite CLIPPERS, one third had HLH gene mutations (PRF1 and UNC13D mutations) (50).
Epidemiology
The incidence and prevalence of CLIPPERS are unknown. Since the original description in 2010 (40), more than 140 cases have been reported (03). Some of these have atypical features that are atypical (large asymmetrical lesions, mass effect, etc.) and do not fulfill the proposed diagnostic criteria (Table 1) (55). The disease could be missed if MRI is done without gadolinium enhancement. With more than 100 cases worldwide over the past 13 years, the disease is considered rare. CLIPPERS was initially thought to affect males and females equally, but in the larger case studies, the male-to-female ratio is approximately 3:1 (49; 55).
Prevention
No means of prevention are known.
Differential diagnosis
A wide range of diseases with brainstem features that mimic CLIPPERS and are provided in Table 2, together with features that may help distinguish these conditions.
Table 2. Differential Diagnosis in CLIPPERS
|
Diagnoses |
Distinctive features | |
|
I. Demyelinating |
Multiple sclerosis |
Periventricular MRI lesions, persistent oligoclonal bands, optic neuritis |
|
Neuromyelitis optica (NMO) and NMO spectrum disease (NMOSD) |
Apq4-IgG, optic neuritis, LETM, area postrema syndrome | |
|
Acute disseminated encephalomyelitis |
Infectious prodrome, widespread confluent contrast-enhancing lesions | |
|
Anti-MOG associated disease |
Anti-MOG-IgG, NMO features | |
|
II. Inflammatory |
Neurosarcoidosis |
ACE, sIL2R-Abs, perihilar node enlargement, pathology |
|
Bickerstaff brainstem encephalitis |
Anti-Gq1b, peripheral involvement, areflexia | |
|
Behçet disease |
HLA-B51, genital and oral ulcers, uveitis, erythema nodosum | |
|
Langerhans-histiocytosis X |
Hypothalamic involvement, lung lesions, confluent MRI lesions | |
|
Sjogren syndrome |
Dry mouth and eyes, ANA, SSA/Ro, SSB/La, minor salivary gland biopsy | |
|
Systemic lupus erythemamatosis |
Fever, malaise, joint pains, muscle pains, kidney disease, antiphospholipid antibody, anti-dsDNA, anticardiolipin antibody | |
|
Wegener granulomatosis |
Upper airway symptoms, nose bleed, kidney disease, pulmonary nodules, ANCA, hematuria | |
|
Paraneoplastic syndrome |
Weight loss, fever, whole-body PET, CSF/serum antibodies | |
|
Anti-GFAP astrocytopathy |
Linear perivascular enhancement on MRI, GFAP-IgG | |
|
KLHL11 encephalitis |
Ataxia, diplopia, vertigo, hearing loss, and cognitive impairment, more common in males, association with germ cell tumors | |
|
Anti-NMDA Encephalitis |
Neuropsychiatric symptoms, seizures, movements disorders, autonomic dysfunction | |
|
III. Neoplastic |
Primary CNS lymphoma |
Confluent enhancement on MRI, CSF monoclonal cells, mass effect |
|
Brainstem glioma |
Mass effect on MRI, no steroid response | |
|
Polyostotic sclerosing histiocytosis (Erdheim-Chester disease) |
Diabetes insipidus, bony lesions, infiltrative lesions with meningeal enhancement | |
|
Hodgkin lymphoma |
Painless cervical and supraclavicular lymphadenopathy, hepato- and splenomegaly, EBV+ | |
|
Brainstem metastases |
Primary tumor on whole-body PET or CT, mass effect, edema | |
|
IV. Vascular |
Primary CNS angiitis |
Prominent headache, sudden exacerbation |
|
Small vascular lesions in brainstem |
Sudden onset, DWI changes | |
|
Posterior reversible encephalopathy syndrome (PRES) |
Seizures, prominent headache, visual disturbances | |
|
V. Infectious |
Viral: HSV, VZV, CMV, EBV, HHV6, HHV7, influenza A, West Nile virus, Japanese encephalitis, enterovirus, JC virus |
CSF PCR finding |
|
Bacterial: Listeria monocytogenes, Mycobacterium tuberculosis, Streptococcus pneumoniae, Tropheryma whippelii, Mycoplasma, Borrelia burgdorferi, Treponema pallidum, Legionella, Salmonella, Brucella, Nocardia |
CSF finding, microscopy, staining, and culture | |
|
Fungal: Blastomyces, Coccidioides, Histoplasma, Aspergillus, Mucor |
CFS finding, microcopy, smear, and culture | |
|
Parasites: neurocysticercosis, toxoplasmosis. |
CSF finding, immunosuppression | |
|
VI: Metabolic |
Pontine myelinolysis |
Chronic hyponatremia, alcohol abuse |
Lacking a specific biomarker in CLIPPERS, there is a potential risk of overdiagnosis. This is suggested by the numerous case descriptions of CLIPPERS mimics. Several diseases can present with punctate or curvilinear MRI changes (48), and a number of red flags were proposed. A careful examination for alternative causes should be performed (61). Red flags include (1) no response to corticosteroids or relapse on a daily dose of prednisone/prednisolone greater than 30 mg, (2) acute onset or progression, (3) lack of brainstem-prominent features, (4) signs of systemic disease, (5) peripheral nervous system involvement, (6) normal brain MRI, (7) significant asymmetrical lesions, and (8) severe edema or mass effect on MRI. Red flags may occur up to 18 months after disease onset (51).
Common mimics of CLIPPERS are: CNS lymphoma, CNS vasculitis, multiple sclerosis, and neurosarcoidosis. Most of these diagnoses may be distinguished based on MRI findings. In CLIPPERS, the punctate lesions are usually small (less than 3 mm) and not confluent, and the T2 hyperintensity does not significantly exceed the gadolinium enhancement. No ring enhancement is seen. Careful repeated examination of CNS cell components with cytology and flow cytometry helps differentiate from lymphoma. Brain biopsy can be needed in cases that have atypical features.
Paraneoplastic disorders, intraparenchymal brainstem metastases, and primary brainstem gliomas should also be considered (22). The latter often have mass effect or significant edema on T2-weighted imaging.
Behçet disease often has brainstem features. The absence of oral and genital ulcers, lack of uveitis and erythema nodosum, and negative HLA-B51 are helpful for distinction (02).
Bickerstaff brainstem encephalitis is part of the spectrum of Miller-Fisher syndrome. Besides ataxia, it may present with peripheral involvement (areflexia); most cases (80%) are associated with anti-Gq1b antibodies. Imaging is often normal or shows nonenhancing brainstem T2 hyperintensities (44).
Langerhans histiocytosis X involves the hypothalamus, causes lung lesions, and has more confluent lesions on MRI.
Polyostotic sclerosing histiocytosis (Erdheim-Chester disease) includes bony lesions, diabetes insipidus, and infiltrative lesions with meningeal involvement on MRI (27).
Infectious causes of rhombencephalitis, such as listeria, enterovirus 70, herpes viruses, and tuberculosis, should also be considered (22). Most of these can be excluded by careful CSF examination, including virus PCR, fungal smear, and bacterial and fungal culture.
Anti-GFAP astrocytopathy has been described as an autoimmune meningoencephalitis. Patients often have prominent headache, papillitis, and medullopathy (14; 60). MRI shows supratentorial linear perivascular enhancement on MRI and anti-GFAP IgG in serum/CSF.
KLHL11-associated rhomboencephalitis can present with brainstem symptoms, typically affecting young males, often associated with germ cell tumors including seminomas. MRI shows brainstem and cerebellar lesions with inflammatory or demyelinating characteristics (29).
Myelin oligodendrocyte glycoprotein (MOG) autoimmunity can mimic CLIPPERS (46; 05; 37; 15; 19). However, it usually can be differentiated from CLIPPERS by the presence of MOG-IgG antibodies, the involvement of the optic nerves, and inflammatory lesions in the spine and conus medullaris.
A proposed diagnostic workup to help differentiate CLIPPERS from alternative causes is provided in Table 2.
Diagnostic workup
Table 3. Diagnostic Workup in CLIPPERS
|
I. Blood |
Blood count |
|
II. CSF |
Cell count, protein, and glucose |
|
III. Imaging |
Contrast-enhanced MRI of brain and spinal cord |
|
IV. Pathology |
Biopsy of abnormalities from PET-CT or CT |
A careful medical history should be obtained, including signs of systemic abnormalities (uveitis, sicca syndrome, arthritis, fever) and a history of oral or genial ulcers.
Initial investigation should include brain MRI and, in cases with medullopathy, also spinal cord MRI. MRI should be gadolinium-enhanced with imaging of vasculature. The MRI hallmark of CLIPPERS is punctate or curvilinear gadolinium enhancement, predominating in the pons and with possible involvement of adjacent regions of the cerebellar peduncles, cerebellum, medulla oblongata, and mesencephalon. This enhancement is described as having a “peppering,” or “salt and pepper” appearance (18).
CLIPPERS before and after high-dose intravenous methylprednisolone (MRI) (1)
T1-weighted MRI images after gadolinium in a patient with CLIPPERS demonstrates punctate and curvilinear gadolinium enhancement in the pons and cerebellum on axial (A1) and sagittal (A2) sections. (Contributed by Dr. Daniel Kondzi...
Gadolinium enhancement can extend into the cervical and, less commonly, thoracic spinal cord.
Supratentorial involvement of the basal ganglia and subcortical white matter and cortical hemispheres can be seen (55). High-field MRI may help demonstrate lesions in regions with normal-appearing brain matter (08). Punctate lesions are usually small (less than 3 mm) and tend to be smaller when found in adjacent regions (40). Larger confluent lesions or asymmetrical lesions were described but are not common and should prompt a careful examination for alternative causes. Slight hyperintensities are seen on T2, but importantly these do not typically exceed the size of gadolinium enhancement (40; 55). Lesions with severe edema or mass effect are not seen and should prompt consideration of malignancies, such as metastases or glioma.
Use of other MRI sequences, such as SWI or PWI, have been used by multiple groups and have described multiple hypointense lesions in the brainstem and cerebellum, likely secondary to chronic inflammation rather than hemorrhages (39; 18). They hypothesize the hypointense lesions with enhancement indicate iron deposition in areas of active inflammation or lymphocytic infiltration (18). Evaluation of available DWI imaging in 22 patients with CLIPPERS found only one patient with minor DWI high signal (55). With multiparametric and quantitative methods, another case showed a decrease in regional cerebral blood flow and cerebral blood volume on perfusion-weighted imaging, as well as elevated density of tracts and a decrease of fraction anisotropy in the pons on diffusion tensor imaging (25; 18).
Cerebral angiogram (MRI or CT angiogram) is important to help exclude cerebral vasculitis. Angiograms are normal in CLIPPERS.
An important feature of CLIPPERS is the prompt clinical and radiological remission with corticosteroid treatment. Clinical remission follows the radiological remission (40). If gadolinium enhancement shows no remission after treatment, alternative diagnoses should be considered (55).
Follow-up MRIs are important in cases of relapse. Atrophy of the pons and cerebellum is sometimes seen with prolonged follow-up, as well as diffuse cerebral atrophy (49).
No blood or CSF biomarker is available for CLIPPERS. Extensive laboratory testing is needed to help distinguish CLIPPERS from other causes. A suggestive panel of tests is outlined in Table 3. These include complete blood count, tests for systemic and paraneoplastic antibodies, hepatitis and HIV screening, and tests for specific inflammatory conditions (anti-MOG, anti-GFAP, anti-KLHL11, anti-NMDA, and anti-Gq1b). Elevated serum IgE was found in some cases (45). Similarly, ANA, ds-DNA, and SSA/SSB were found in some cases but without clinical correlation to a specific syndrome (40; 45); the significance of these is unknown.
CSF analysis is important in all patients with suspected CLIPPERS. The most common pathological feature seen is a mild protein elevation (44 to 114 mg/dl). Some cases have a slightly elevated lymphocytic pleocytosis (9 to 114 cells ul/L), but a marked pleocytosis should raise concern for an alternative cause. Oligoclonal bands are occasionally seen and are often transient (49; 48). CSF analysis is important for the exclusion of infection (Table 3), and cytology and flow cytometry is recommended as CNS lymphoma may mimic CLIPPERS.
Whole-body PET-CT or CT of thorax and abdomen can help exclude underlying malignancy with intracerebral metastases or paraneoplastic conditions but may also help diagnose systemic inflammation in neurosarcoidosis or rheumatological disorders. Biopsy of changes found on whole-body imaging is recommended.
Brain biopsy in CLIPPERS remains somewhat controversial. Reports of lymphoma mimicking CLIPPERS have led some to recommend brain biopsy in all patients suspected (30). Pathology findings are, however, not specific for CLIPPERS and should be used to rule out other causes. Even though brain biopsy in regions typically affected by CLIPPERS is complicated (eloquent areas: brainstem, cerebellum, and spinal cord), it should be considered in patients with atypical findings. Brain biopsy should target an atypical enhancing lesion when noninvasive investigations remain inconclusive (51). Typical cases of CLIPPERS can be diagnosed to a probable level without brain biopsy (Table 1) (55).
Management
Treatment of CLIPPERS is based on case series and individual case reports. No randomized controlled trials are currently available due to the rarity of the condition. Treatment should be started early (55).
Initial treatment. High-dose intravenous corticosteroids (1 g intravenous methylprednisolone daily for 3 to 5 days) are recommended (49; 55; 61). In some cases, treatment was expanded to 10 days when no clinical effect was seen. Clinical improvement or remission is usually seen within days. Oral prednisone (1 mg/kg per day) or six courses of cyclophosphamide and azathioprine or immunoglobulin did not improve clinical symptoms during an attack (47).
Chronic treatment. Patients should be continued on oral corticosteroid (1 mg/kg prednisone) with a very slow taper (eg, 5 mg per week to 20 mg) (55). Alternatively, oral prednisone can be started at a dose of 1 mg/kg/d for 4 to 8 weeks, then tapered by 10 mg every 2 weeks to 20 mg/day, then 2.5 mg every 4 weeks to 10 mg, then 1 mg every 4 weeks until 5 mg/day (47).
Relapse is common while tapering corticosteroids but usually occurs at doses less than 20 mg daily (49). The addition of a steroid-sparing agent should be considered when starting oral corticosteroids (61). However, these are often insufficient in monotherapy, and continuous oral corticosteroid treatment is often necessary (13).
Steroid-sparing agents in doses higher than the ones used for rheumatological conditions are often needed (55). Used agents include azathioprine (2.5 mg/kg/day), methotrexate (target dose 22.5 mg weekly), and mycophenolate mofetil (2 g per day divided in individual doses) (61).
Treatment with prednisone above 20 mg/day should be maintained until the steroid-sparing agent is effective. Relapse during or after cessation of immunotherapy should be treated with repeated high-dose intravenous corticosteroid (61).
The efficacy of anti-CD20 treatment with rituximab was described in some cases, even though only a limited number of B cells were seen in the lesions (49; 10). This is in line with increasing evidence that B cells are important regulators of T cell function. Intravenous immunoglobulins appear ineffective (16). Hydroxychloroquine was reported effective in one case and ineffective in others (40; 53). Antituberculous therapy was reported in one case, but efficacy was not confirmed (35). Chronic treatment with leflunomide was effective in one case (12) as well as chronic treatment with cladribine in another case (54). Treatment with tacrolimus and tocilizumab was also trialed successfully in another case (41).
No data on the length of treatment are available. Some recommend treatment for 12 months before withdrawing immunotherapy (61). MRI follow-up should be performed after treatment cessation as MRI findings may precede clinical symptoms. Further studies are needed to determine the most efficient chronic treatment.
Cautions and side effects. Corticosteroids and steroid-sparing immunosuppressants are associated with a wide range of side effects.
With prolonged high-dose corticosteroid treatment, additional prophylactic agents, including PJP (pneumocystis jirovecii pneumonia) prophylaxis, calcium with vitamin D, and proton pump inhibitors, are needed. Bone densitometry testing is recommended. Treatment with bisphosphonate may be necessary if osteoporosis is present or occurs during treatment. Monitoring for hyperglycemia is recommended. Abrupt discontinuation of steroids should be avoided due to the risks of adrenal crisis.
Intravenous methylprednisolone often causes psychosis, hyperglycemia, and insomnia. Additional side effects seen more commonly with long-term oral prednisone include infection, osteoporosis, avascular necrosis of the hip, Cushingoid appearance, skin thinning and easy bruising, depression, cataracts, hypertension, weight gain, and edema.
Blood monitoring is necessary for patients taking steroid-sparing immunosuppressants. Laboratory testing for complete blood count, renal function, and liver function should be performed before the initiation of treatment and then once weekly for 1 month, twice weekly for 1 month, and monthly thereafter for the duration of treatment with methotrexate or azathioprine.
With methotrexate treatment, folic acid supplementation is needed. Methotrexate may result in myelosuppression, nephrotoxicity, liver damage, pulmonary fibrosis, toxic epidermal necrolysis, and an increased risk of infection.
Mycophenolate mofetil is associated with infection, increased risk of malignancy (lymphoma, skin cancers, and others), diarrhea, hypertension, hepatitis, myelosuppression, and renal failure. Mycophenolate mofetil use may be limited by high cost.
Before starting azathioprine, testing thiopurine-S-methyltransferase (TPMT) activity is necessary, as patients with low enzyme activity are at increased risk of toxicity from the drug. Azathioprine is associated with infection, malignancy (lymphoma, skin cancers, and others), nausea, macrocytic anemia, skin rash, hypersensitivity reaction, pancreatitis, and elevated liver function tests.
Rituximab may cause infusion reactions and increase the risk of infection (including progressive multifocal leukoencephalopathy); it may increase the risk of hematological malignancy and may cause hypotension and gastrointestinal perforations. With rituximab, some recommend periodic monitoring of the CD19 count every 6 to 9 months and consider another round of rituximab only if CD19 cells have been replenished or clinical deterioration occurs, whereas others base this decision on clinical factors alone.
Side effects associated with cyclophosphamide include infection, increased risk of malignancy (lymphoma, skin neoplasms, and others), nausea and vomiting, hemorrhagic cystitis, alopecia, and infertility.
Outcomes
CLIPPERS is a progressive brainstem syndrome with an often-dramatic response to corticosteroids. The majority of patients have some residual disability after treated relapses (EDSS of 1.9) (49). Relapses are common, especially with corticosteroid doses less than 20 mg/day. In a study of 12 patients, the annualized relapse rate was 0.5 (0.25 to 2.8 without long-term corticosteroid treatment) (49). Some patients progress even with aggressive immunotherapy (55). Even after multiple attacks, most patients had only moderate disability and remained ambulatory at the last follow-up (Median EDSS of 3) (49). In a retrospective study of 23 CLIPPERS patients with a median follow-up of 44 months, the median mRS was 1 (55). Five patients were dead at follow-up (median 27 months from symptom onset) due to sepsis (n=2), systemic B cell lymphoma (n=1), progressive neurologic disease (n=1), and uncertain cause (n=1).
Special considerations
Pregnancy
No information is available concerning pregnancy in patients with CLIPPERS. Steroid-sparing agents can be teratogenic and are not recommended in pregnant women, and proper birth control methods should be used for women of childbearing age.
Anesthesia
No information regarding anesthesia in patients with CLIPPERS is available.
Media
References
- 01
- Acir I, Sezen A, Serhat Aygun M, Altintas A. Diagnostic challenges in SLIPPERS síndrome: Case report. Mult Scler J Exp Transl Clin 2025;11(1):20552173241312534. PMID 39895881
- 02
- Al-Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009;8(2):192-204. PMID 19161910
- 03
- Al-Chalabi M, DelCimmuto NR, Beran A, et al. Clinical characteristics, management, and outcomes of CLIPPERS: a comprehensive systematic review of 140 patients from 100 studies. Mult Scler Relat Disord 2022;68:104112. PMID 36029706
- 04
- Armand C, Graber J, Lado F, LaSala P, Weidenheim K. SLIPPERS: supratentorial lymphocytic inflammation with parenchymal perivascular enhancement responsive to steroids: A case report. Neurology 2015;84(14 Supplement):P5.118.
- 05
- Berzero G, Taieb G, Marignier R, Younan N, Savatovsky J, Leclercq D, Psimaras D. CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies. Eur J Neurol 2018;25(2):e16-7. PMID 29356261
- 06
- Biotti D, Deschamps R, Shotar E, et al. CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Pract Neurol 2011;11(6):349-51. PMID 22100944
- 07
- Blaabjerg M, Hemdrup AL, Drici L, et al. Omics-based approach reveals complement-mediated inflammation in chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Front Immunol 2018;9:741. PMID 29740431
- 08
- Blaabjerg M, Ruprecht K, Sinnecker T, et al. Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI. Neurol Neuroimmunol Neuroinflamm 2016;3(3):e226. PMID 27144217
- 09
- Buttmann M, Metz I, Brecht I, et al. Atypical chronic lymphocytic inflammation with pontocerebel-lar perivascular enhancement responsive to steroids (CLIPPERS), primary angiitis of the CNS mimicking CLIPPERS or overlap syndrome? A case report. J Neurol Sci 2013;324(1-2):183-6. PMID 23149266
- 10
- Cipriani VP, Arndt N, Pytel P, Reder AT, Javed A. Effective treatment of CLIPPERS with long-term use of rituximab. Neurol Neuroimmunol Neuroinflamm 2018;5(3):e448. PMID 29511706
- 11
- De Graaff HJ, Wattjes MP, Rozemuller-Kwakkel AJ, Petzold A, Killestein J. Fatal B-cell lymphoma following chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids following influenza vaccination. JAMA Neurol 2013;70(7):915-8. PMID 23649857
- 12
- Didier PJ, Adrián ML, Paola SA, et al. CLIPPERS syndrome responsive to leflunomide: a case report. Mult Scler Relat Disord 2018;25:265-7. PMID 30149302
- 13
- Dudesek A, Rimmele F, Tesar S, et al. CLIPPERS: chronic lymphocytic inflammation with pon-tine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders. Clin Exp Immunol 2014;175(3):385-96. PMID 24028073
- 14
- Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 2016;73(11):1297-307. PMID 27618707
- 15
- Ferilli MA, Papi C, Sabatelli M, Colosimo C, Iorio R. MOG autoimmunity mimicking CLIPPERS syndrome: case report and literature review. J Neuroimmunol 2022;367:577875. PMID 35490445
- 16
- Gabilondo I, Saiz A, Graus F, Villoslada P. Response to immunotherapy in CLIPPERS syndrome. J Neurol 2011;258(11):2090-2. PMID 21553269
- 17
- Galazky I, Büntjen L, Voges J, Sandalcioglu IE, Mawrin C, Haghikia A. Brain biopsy in patients with CLIPPERS syndrome: why and when. Ther Adv Neurol Disord 2022;15:17562864211062821. PMID 35126669
- 18
- Grasso D, Borreggine C, Prencipe G. Role of advanced MRI in diagnosing and evolutive follow-up to treatment in a case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Radiol Case Rep 2025;20(11):5458-65. PMID 40821365
- 19
- Guo J, Bu Y, Liu W. Case report: a case with MOGAD and Anti-NMDAR encephalitis overlapping syndrome mimicing radiological characteristics of CLIPPERS. Front Immunol 2022;13:832084. PMID 35493443
- 20
- Hillesheim PB, Parker JR, Parker JC Jr, Escott E, Berger JR. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids following influenza vaccination. Arch Pathol Lab Med 2012;136(6):681-5. PMID 22646278
- 21
- Jones JL, Dean AF, Antoun N, Scoffings DJ, Burnet NG, Coles AJ. ‘Radiologically compatible CLIPPERS’ may conceal a number of pathologies. Brain 2011;134(Pt 8):e187. PMID 21653537
- 22
- Jubelt B, Mihai C, Li TM, Veerapaneni P. Rhombencephalitis/brainstem encephalitis. Curr Neurol Neurosci Rep 2011;11(6):543-52. PMID 21956758
- 23
- Kastrup O, van de Nes J, Gasser T, Keyvani K. Three cases of CLIPPERS: a serial clinical, laboratory, and MRI follow-up study. J Neurol 2011;258:2140-6. PMID 21556878
- 24
- Kerrn-Jespersen BM, Lindelof M, Illes Z, et al. CLIPPERS among patients diagnosed with non-specific CNS neuroinflammatory diseases. J Neurol Sci 2014;343(1-2):224-7. PMID 24954086
- 25
- Korostyshevskaya AM, Stankevich JA, Vasilkiv LM, et al. CLIPPERS: multiparametric and quantitative MRI features. Radiol Case Rep 2022;18(1):368-76. PMID 36411846
- 26
- Koumasopoulos E, Spiteri EA, Vakrakou AG, et al. Central nervous system B-cell lymphoma in a patient diagnosed with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids: A case report. SAGE Open Med Case Rep 2025;13:2050313X251316764. PMID 39897570
- 27
- Lachenal F, Cotton F, Desmurs-Clavel H, et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol 2006;253(10):1267-77. PMID 17063320
- 28
- Li EC, Lai QL, Cai MT, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): contemporary advances and current controversies. J Neurol 2024;271(4):1747-66. PMID 38286842
- 29
- Li J, Bai L, Yuan Y, Zhai J, Wang M. KLHL11-associated rhomboencephalitis presenting as clippers-like syndrome. Neurol Sci 2025;46(3):1439-41. PMID 39522106
- 30
- Limousin N, Praline J, Motica O, et al. Brain biopsy is required in steroid-resistant patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). J Neurooncol 2012;107(1):223-4. PMID 21968945
- 31
- Lin AW, Das S, Fraser JA, et al. Emergence of primary CNS lymphoma in a patient with findings of CLIPPERS. Can J Neurol Sci 2014;41(4):528-9. PMID 24878484
- 32
- Link TA, Köcher SE, Dohmen H, Behr R, Neumann-Haefelin T. CLIPPERS-syndrom: eine erkrankung mit vielen gesichtern – ein fallbericht [CLIPPERS syndrome - a disorder with many faces- a case report]. Fortschr Neurol Psychiatr 2019;87(10):571-5. German. PMID 31627239
- 33
- Ma Y, Sun X, Li W, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with intracranial Epstein-Barr virus infection: a case report. Medicine (Baltimore) 2016;95(46):e5377. PMID 27861371
- 34
- Mashima K, Suzuki S, Mori T, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after treatment for Hodgkin's lymphoma. Int J Hematol 2015;102(6):709-12. PMID 26243623
- 35
- Mele N, Guiraud V, Labauge P, Oppenheim C, Mas JL, Taieb G. Effective antituberculous therapy in a patient with CLIPPERS: New insights into CLIPPERS pathogenesis. Neurol Neuroimmunol Neuroinflamm 2014;1(1):e6. PMID 25340062
- 36
- Nakamura R, Ueno Y, Ando J, et al. Clinical and radiological CLIPPERS features after complete remission of peripheral T-cell lymphoma, not otherwise specified. J Neurol Sci 2016;364:6-8. PMID 27084205
- 37
- Obeidat AZ, Block AN, Hooshmand SI. "Peppering the pons": CLIPPERS or myelin oligodendrocyte glycoprotein associated disease? Mult Scler Relat Disord 2021;51:102874. PMID 33714127
- 38
- Ortega MR, Usmani N, Parra-Herran C, et al. CLIPPERS complicating multiple sclerosis causing concerns of CNS lymphoma. Neurology 2012;79(7):715-6. PMID 22855867
- 39
- Pesaresi I, Sabato M, Desideri I, Puglioli M, Moretti P, Cosottini M. 3.0T MR investigation of CLIPPERS: role of susceptibility weighted and perfusion weighted imaging. Magn Reson Imaging 2013;31(9):1640-2. PMID 23969198
- 40
- Pittock SJ, Debruyne J, Krecke KN, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Brain 2010;133(9):2626-34.** PMID 20639547
- 41
- Rempe T, Becktepe JS, Metz I, et al. A case of CLIPPERS syndrome responsive to tocilizumab. Neurol Neuroimmunol Neuroinflamm 2019;6(3):e545. PMID 30882019
- 42
- Saenz-Silva J, Ordinola Navarro A. CLIPPERS syndrome after vaccination. an unusual ASIA presentation. Reumatol Clin (Engl Ed) 2023;19(3):168-70. PMID 36906391
- 43
- Sempere AP, Mola S, Martin-Medina P, Bernabeu A, Khabbaz E, Lopez-Celada S. Response to immunotherapy in CLIPPERS: clinical, MRI, and MRS follow-up. J Neuroimaging 2013;23(2):254-5. PMID 21848680
- 44
- Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2013;84(5):576-83. PMID 22984203
- 45
- Simon NG, Parratt JD, Barnett MH, et al. Expanding the clinical, radiological and neuropathological phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). J Neurol Neurosurg Psychiatry 2012;83(1):15-22. PMID 22056964
- 46
- Symmonds M, Waters PJ, Küker W, Leite MI, Schulz UG. Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS. Neurology 2015;84(11):1177-9. PMID 25681455
- 47
- Taieb G, Allou T, Labauge P. Therapeutic approaches in CLIPPERS. Curr Treat Options Neurol 2017;19(5):17. PMID 28386850
- 48
- Taieb G, Duran-Peña A, de Chamfleur NM, et al. Punctate and curvilinear gadolinium enhancing lesions in the brain: a practical approach. Neuroradiology 2016;58(3):221-35. PMID 26700824
- 49
- Taieb G, Duflos C, Renard D, et al. Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol 2012;69(7):847-55.** PMID 22777259
- 50
- Taieb G, Kaphan E, Duflos C, et al. Hemophagocytic lymphohistiocytosis gene mutations in adult patients presenting with CLIPPERS-like syndrome. Neurol Neuroimmunol Neuroinflamm 2021;8(3):e970. PMID 33658321
- 51
- Taieb G, Mulero P, Psimaras D, et al. CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. J Neurol Neurosurg Psychiatry 2019;90(9):1027-38. PMID 31072955
- 52
- Taieb G, Uro-Coste E, Clanet M, et al. A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERS. J Neurol Sci 2014;344(1-2):224-6. PMID 24990651
- 53
- Tan BL, Agzarian M, Schultz DW. CLIPPERS: Induction and maintenance of remission using hydroxychloroquine. Neurol Neuroimmunol Neuroinflamm 2015;2(1):e56. PMID 25610881
- 54
- Thebault S, Bergman H, Atkins HL, Freedman MS, Brooks J. CLIPPERS responsive to cladribine as a durable steroid-sparing agent. Neurol Neuroimmunol Neuroinflamm 2022;10(1):e200060. PMID 36396449
- 55
- Tobin WO, Guo Y, Krecke KN, et al. Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 2017;140(9):2415-25.** PMID 29050399
- 56
- Tohge R, Nagao M, Yagishita A, Matsubara S. A case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) in East Asia. Intern Med 2012;51(9):1115-9. PMID 22576399
- 57
- Weng CF, Chan DC, Chen YF, Liu FC, Liou HH. Chronic hepatitis B infection presenting with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a case report. J Med Case Rep 2015 19;9:266. PMID 26582039
- 58
- Xu J, Feng F, Li M, et al. Analysis of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) imaging and clinical manifestations in 4 cases. [Chinese.] J Clin Radiol 2017;36:922-6.
- 59
- Yi F, Tian Y, Chen XY, et al. Two cases of CLIPPERS with increased number of perivascular CD20-positive B lymphocytes. Brain 2018;141(10). PMID 30202949
- 60
- Yin HX, Zhou Y, Xu Y, et al. A Case report of autoimmune glial fibrillary acidic protein astrocytopathy diagnosed after long term diagnosis of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Front Neurol 2020;11:598650. PMID 33281735
- 61
- Zalewski NL, Tobin WO. CLIPPERS. Curr Neurol Neurosci Rep 2017;17(9):65. PMID 28726127
- 62
- Zhang L, Liu XH, Jin F, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma: Comparison of clinical features and risk factors suggestive of underlying lymphomas. J Clin Neurosci 2019;66:156-64. PMID 31088767
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Veronica P Cipriani MD MS
Dr. Cipriani of the University of Chicago Medical Center received consulting fees from Genetech and TG Therapeutics as a speakers bureau member and consulting fees from TG Therapeutics and Sanofi; Dr. Cipriani also served as a steering committee member for a clinical trial involving Novartis.
See Profile
Editor
-
Anthony T Reder MD
Dr. Reder of the University of Chicago received honorariums from Genentech, Genzyme, and TG Therapeutics for service on advisory boards and as a consultant and stock options from NKMax America for advisory work and an unrestricted lab research grant from BMS.
See Profile
Former Authors
- Eoin P Flanagan MBBch
- Sean J Pittock MD
- Daniel Kondziella MD MSc PhD FEBN
- Morten Blaabjerg MD PhD
- Widad Abou Chaar MD
Patient Profile
- Age range of presentation
-
- 6 to 65+ years
- Sex preponderance
-
- Male:female, >3:1
- Heredity
-
- none
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Other encephalitis, myelitis and encephalomyelitis: G04.8
- ICD-11
-
- Paraneoplastic or autoimmune disorders of the central nervous system, brain or spinal cord: 8E4A.0
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuropharmacology & Neurotherapeutics
Upadacitinib
May. 14, 2026
-
General Child Neurology
Guillain-Barre syndrome in children
Apr. 24, 2026
-
Neuromuscular Disorders
Efgartigimod alfa-fcab
Apr. 23, 2026
-
Neuromuscular Disorders
Efgartigimod alfa and hyaluronidase-qvfc
Apr. 23, 2026
-
Neuropharmacology & Neurotherapeutics
Ofatumumab
Apr. 23, 2026
-
Neuroimmunology
Neuropathies associated with cryoglobulinemia
Mar. 29, 2026
-
Neuroimmunology
Rheumatoid arthritis: neurologic manifestations
Mar. 20, 2026